A 10 mg BPC-157 vial reconstituted with 5 mL of bacteriostatic water yields a 2 mg/mL concentration identical to the standard 5 mg / 2.5 mL preparation, so the same mL values apply: 250 g = 0.125 mL, 500 g = 0.25 mL
Also, BPC 157 administration attenuates prolonged bleeding and thrombocytopenia after amputation, organ perforation, and anticoagulant use or prolonged major vessel occlusion (Stupnisek et al., 2012
The nitric oxide enhancement from the arginate salt form is particularly relevant for athletic applications
However, high-dose niacin (as a medication for cholesterol) is generally not recommended during breastfeeding, because significant amounts could enter milk and cause unwanted effects in the nursing infant (flushing, for example)
Oral BPC-157 Research Research into oral BPC-157 administration has focused particularly on gastrointestinal tract applications including studies on gastric ulceration, intestinal permeability, and inflammatory bowel models where local gut exposure may be mechanistically relevant
HIGHLIGHTS: Stable BPC-157, a novel anti-ulcer peptide (1) BPC-157: Healing in different tissues Tendon Healing (4) Bone healing BPC-157 & Neuroprotective effect Effect on Spinal Cord Injury Blood Pressure Tendon Healing (4) Bone healing Stable BPC-157 as anti-ulcer agent (1) Stable gastric pentadecapeptide BPC 157 is a novel anti-ulcer peptide, used in trials for the treatment of ulcerative colitis and now multiple sclerosis, lethal dose (dosage required to kill 1% of the test population, LD1) not reported
